Clinical trials: Cystic Fibrosis Pulmonary Exacerbation
Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation
Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients
There is established evidence that adult patients with Cystic Fibrosis (CF) may have altered antibiotic pharmacokinetics compared with non-CF patients.
- Conditions
- Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation, Pseudomonas Aeruginosa Infection
- Trial name
- NCT02421120
- Testing
- Ceftolozane/Tazobactam
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- Joseph L. Kuti, PharmD
Cystic Fibrosis
Comprehensive Exercise Training Program During Hospitalization for an Acute CF Exacerbation
This protocol was designed to assess if when subjects with CF are admitted to the hospital for a pulmonary exacerbation if a comprehensive exercise program (moderate to high intensity aerobic, resistance, flexibility and balance…
- Trial name
- NCT01759342
- Testing
- Aerobic exercise, Resistance exercise, Flexibility and postural exercise
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Alabama at Birmingham
Ototoxicity
SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity
The primary objective of this study is to determine the safety and efficacy of SPI-1005 treatment in CF patients with active pulmonary exacerbation that are receiving an IV course of tobramycin, determined by comparing hearing…
- Trial name
- NCT02819856
- Testing
- SPI-1005 Ebselen 200mg Capsule x1, SPI-1005 Ebselen 200mg Capsule x2, SPI-1005 Ebselen 200mg Capsule x3
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Sound Pharmaceuticals, Incorporated
Cystic Fibrosis
Streamlined Treatment of Pulmonary Exacerbations in Pediatrics
The STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of two antibiotic treatment strategies for the management of outpatient…
- Trial name
- STOP PEDS RCT (NCT06654752)
- Testing
- Immediate Oral Antibiotics, Tailored Treatment: Oral Antibiotics only if Additional Treatment needed
- Where
- 33 sites in United States, Canada
- Volunteers
- 430 people
- Sponsor
- University of Washington, the Collaborative Health Studies Coordinating Center
Vitamin D Deficiency, Cystic Fibrosis
Efficacy of Intensive Cholecalciferol Monitoring and Supplementation on Serum vitD Levels in Pediatric Patients With CF
Cystic fibrosis (CF) is an autosomal recessive disease caused by alterations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene, characterized by multisystemic alterations, mainly in the lung, intestine…
- Conditions
- Vitamin D Deficiency, Cystic Fibrosis, Bone Density, Low, Inflammation Chronic
- Trial name
- NCT05276960
- Testing
- Cholecalciferol Pill
- Where
- Mexico
- Volunteers
- 40 people
- Sponsor
- Hospital Infantil de Mexico Federico Gomez
Cystic Fibrosis
Parameters to Assess Response to Intra-Venous Antibiotic Treatment for Pulmonary Exacerbations in Cystic Fibrosis
Cystic fibrosis (CF) is a multisystem disease characterized by viscid secretions in multiple organ systems. Lung infection and damage account for most of the disease burden.
- Trial name
- PRIVATE (NCT04016571)
- Where
- United Kingdom
- Volunteers
- 31 people
- Sponsor
- Belfast Health and Social Care Trust
Cystic Fibrosis, Lung Infection
Pilot Observational Study to Determine Feasibility of a Standardized Treatment of Pulmonary Exacerb. in Patients With CF
The goal of this research study is to better understand current treatment practices for pulmonary exacerbations (lung infections) and whether the Cystic Fibrosis National Patient Registry (CFFNPR)can be used for this type of…
- Conditions
- Cystic Fibrosis, Lung Infection, Cystic Fibrosis Pulmonary Exacerbation
- Trial name
- STOP-OB-13 (NCT02109822)
- Where
- 12 sites in United States
- Volunteers
- 220 people
- Sponsor
- University of Washington
Cystic Fibrosis Pulmonary Exacerbation
Pharmacokinetic Study of Extended Infusion Meropenem in Adult Cystic Fibrosis Patients
Meropenem is an intravenous antibiotic commonly used to treat acute exacerbation of respiratory infections in cystic fibrosis. The research study aims to determine if a different method of infusing the drug over 3 hours or…
- Trial name
- NCT01158937
- Testing
- Meropenem Infusion
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- Unity Health Toronto
Cystic Fibrosis
PEP and OPEP Devices in Cystic Fibrosis
Cystic fibrosis (CF) is the most common severe autosomal recessive genetic disease in Caucasians. The CFTR (cystic fibrosis transmembrane regulator) gene, which encodes the chloride channel of the epithelial cell membrane, is…
- Trial name
- NCT05801952
- Testing
- Aerobika* OPEP, PARI O-PEP (Flutter), PARI PEP® S System
- Where
- Poland
- Volunteers
- 60 people
- Sponsor
- National Institute for Tuberculosis and Lung Diseases, Poland
Cystic Fibrosis, Pseudomonas Aeruginosa
Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis
The aim of this trial was to compare the safety and efficacy of courses of tobramycin and ceftazidime, administered intravenously as either thrice daily short infusions or 24 h continuous infusion, in cystic fibrosis patients…
- Conditions
- Cystic Fibrosis, Pseudomonas Aeruginosa, Pulmonary Exacerbation
- Trial name
- NCT00333385
- Testing
- ceftazidime
- Where
- 15 sites in France
- Volunteers
- 120 people
- Sponsor
- Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche
Cystic Fibrosis
Effects of Vitamin D Supplementation on Lung Function in an Acute Pulmonary Exacerbation of Cystic Fibrosis
Vitamin D insufficiency is common in patients with cystic fibrosis. The investigators study will examine a large dose of vitamin D given to patients who have cystic fibrosis and are admitted to the hospital for a pulmonary…
- Trial name
- NCT00788138
- Testing
- Vitamin D3
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Emory University
Cystic Fibrosis Pulmonary Exacerbation
Prednisone in Cystic Fibrosis Pulmonary Exacerbations
This will be a 5 year randomized, double blind, placebo controlled trial of 7 days of oral prednisone in cystic fibrosis (CF) patients receiving intravenous (IV) antibiotic treatment for a pulmonary exacerbation at the Hospital…
- Trial name
- PIPE (NCT03070522)
- Testing
- Prednisone
- Where
- 12 sites in Canada
- Volunteers
- 76 people
- Sponsor
- The Hospital for Sick Children
Cystic Fibrosis Pulmonary Exacerbation
Glucose Monitoring in Youth With Cystic Fibrosis During Pulmonary Exacerbations
The goal of this study is to investigate the prevalence of dysglycemia with continuous glucose monitoring (CGM) obtained during pulmonary exacerbations, both outpatient and inpatient, in youth with cystic fibrosis (CF).
- Trial name
- GeM-PEx (NCT06546943)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Colorado, Denver
Cystic Fibrosis, Airway Clearance Impairment
IPV vs CPT for Airway Clearance During CF Exacerbation
Intrapulmonary Percussive Ventilation (IPV) will show greater improvements in Forced Expiatory Volume in 1 second (FEV1) shorter duration of stay, and greater time to next pulmonary exacerbation in pediatric Cystic Fibrosis…
- Trial name
- NCT03261219
- Testing
- Intrapulmonary Percussive ventilation, Chest Physiotherapy Vest (Incourage)
- Sponsor
- University of Florida
Cystic Fibrosis
Do Physiotherapy Techniques Improve Posture During Admission for a Chest Infection in Adults With Cystic Fibrosis?
Hypothesis: The addition of a series of musculoskeletal techniques to normal optimal care for the treatment of a respiratory exacerbation in inpatient adults with cystic fibrosis, will lead to further improvements in pain…
- Trial name
- NCT00806884
- Testing
- Physiotherapy Musculoskeletal Treatment, Control group measurements
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Cystic Fibrosis (CF), Cystic Fibrosis Pulmonary Exacerbation
Understanding Inflammation, InFection and Interventions in Severe Exacerbations of Cystic Fibrosis
The UNIFIED-CF study is an observational study designed to investigate the impacts of treatment given for severe pulmonary exacerbations in people living with cystic fibrosis (pwCF).
- Trial name
- UNIFIED-CF (NCT07484607)
- Where
- 6 sites in United Kingdom
- Volunteers
- 200 people
- Sponsor
- Alexander Horsley
Cystic Fibrosis, Children
Prevention of CF Exacerbation in Childhood: PREVEC Study
Pulmonary exacerbations of CF are an important cause for the experienced disability of patients, respiratory symptoms, and decreases in lungfunction, which require antibiotic therapy at home or in the hospital.
- Conditions
- Cystic Fibrosis, Children, Exhaled Breath Condensate, Non-invasive Inflammatory Markers
- Trial name
- PREVEC (NCT01241890)
- Where
- 3 sites in Netherlands
- Volunteers
- 49 people
- Sponsor
- Maastricht University Medical Center
Cystic Fibrosis (CF), Cystic Fibrosis Pulmonary Exacerbation
Identifying the Causes and Risk Factors of Pulmonary Exacerbations in Cystic Fibrosis
The CF-Tracker study is a community surveillance study, designed to understand the causes of exacerbations in people with cystic fibrosis (CF) (pwCF).
- Trial name
- CF-Tracker (NCT06940531)
- Where
- 18 sites in United Kingdom
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Alexander Horsley
Cystic Fibrosis
Early Intervention in Cystic Fibrosis Exacerbation
Individuals with cystic fibrosis (CF) develop chronic lung infections and suffer intermittent acute exacerbations of their lung disease.
- Trial name
- eICE (NCT01104402)
- Testing
- Home lung function and symptom monitoring
- Where
- 3 sites in United States
- Volunteers
- 267 people
- Sponsor
- Johns Hopkins University
Pulmonary Cystic Fibrosis
Standardized Treatment of Pulmonary Exacerbations II
Cystic fibrosis (CF), a life-shortening genetic disease, is marked by acute episodes during which symptoms of lung infection increase and lung function decreases.
- Trial name
- STOP2 (NCT02781610)
- Testing
- Standard of care IV antibiotic(s)
- Where
- 58 sites in United States, Canada
- Volunteers
- 982 people
- Sponsor
- Chris Goss